PT Royal Prima Tbk.

prim

-1.82%

Overview

PRIM Overview

PT Royal Prima Tbk is an Indonesia based company primarily engaged in operating Royal Prima General Hospital. The Company’s portfolio includes orthopedic specialist, eye specialist, neuro specialist, internal medicine specialist, obstetrics and gynecology specialist, cardiologist, lung specialist, pediatric specialist and urology specialist. The Company provides general surgeon, surgical oncology specialist, plastic surgeon, pediatric surgeon, neurosurgery specialist, digestive surgery specialist, skin and gender specialist, psychiatrist, dental polyclinic, oral surgeon, vascular surgeon, renal and hypertension subspecialist, diabetes and metabolic endocrine subspecialist. The Company’s services include NICU, baby room, physiotherapy, emergency room, endoscopy and birthing room.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: PRIM

Development
Market Cap.
IDR 182.43Billion

~$11.20M USD

Industry
Healthcare Providers
Sub-Industry
Healthcare Providers
Sector
Healthcare

Valuation

PRIM Valuation Metrics

54

IDR
-1.8%

Closing Price on 2024-06-14

Price to Equity

476.74

P/E

At 476.74x P/E TTM, PRIM.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 22.1x).

Price to Book

0.19

P/B

At 0.19x P/B TTM, PRIM.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Sales

0.66

P/S

At 0.66x P/S TTM, PRIM.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Valuing PT Royal Prima Tbk. based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Royal Prima Tbk. relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
8.56x
Price/Forward Earnings
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
-
PEG Ratio
10.72x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of PRIM stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 476.74x is above the ID market average of 8.07x and is trading at a premium to peers in the Healthcare Equipment & Providers sector (22.10x). In fact, less than 25% of its peers trade at a higher P/E ratio than PRIM.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 0.19x is below the peers average of 1.53x in the Healthcare Equipment & Providers sector. In fact, less than 25% of its peers trade at a lower P/B ratio than PRIM.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.66x is below the peers average of 2.42x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of PRIM's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. PRIM's P/CF ratio of 8.56x is considered healthy by analysts.

Peers

PRIM Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.39T28.96T 30.94T 2.87T 25.243.23
MIKAPT Mitra Keluarga Karyasehat Tbk.41.72T7.81T 4.48T 0.97T 42.826.83
SILOPT Siloam International Hospitals Tbk.33.75T11.42T 11.56T 0.98T 34.614.27
SRAJSejahteraraya Anugrahjaya Tbk26.40T5.62T 2.71T -0.02T -1327.5114.19
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk22.20T4.25T 3.71T 1.04T 21.335.85
HEALPT Medikaloka Hermina Tbk.20.03T9.20T 6.14T 0.52T 38.564.80
TSPCTempo Scan Pacific Tbk8.97T11.93T 13.33T 1.02T 8.831.11
PRAYPT Famon Awal Bros Sedaya Tbk8.86T4.81T 1.93T 0.21T 43.073.08
SOHOPT Soho Global Health Tbk8.63T5.13T 8.58T 0.44T 19.583.42
OMEDPT Jayamas Medica Industri Tbk5.38T2.65T 1.77T 0.27T 20.212.36
Competitiveness Recap of PRIM stock
WeightNotesScore
High
At a market cap of IDR 182.43 billion, PRIM.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 476.74, PRIM.JK ranks 1 out of 10 companies in the Healthcare sector for P/E value. The average PE is -61.67 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. false

Medium
At a PE of 476.74, PRIM.JK is trading at a higher PE than that of its subsector peers in Healthcare Equipment & Providers (median of 22.10). false

Medium
At a revenue of IDR 0.28 trillion, PRIM.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.00 trillion, PRIM.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of PRIM

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 24.79% against the IDX average of +13.1%.

Healthcare Equipment & Providers sector overview
No data is available for PRIM at the moment.
Future growth prospect of PRIM
WeightNotesScore
High
PRIM's projected growth rate of 24.79% is above the ID market average of 13.14%.

High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 24.32% in 2025. This number is higher than the previous year 2024's growth rate of 11.10%. This bodes well for PRIM's revenue growth prospects in the next 2 years.

Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 18.17% in 2025. This number is higher than the previous year 2024's EPS growth of -1.27%. This bodes well for PRIM's earnings growth prospects in the next 2 years.

Medium
PRIM and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.74% in 2025 while revenue growth is projected to increase by 20.17%. These macroeconomic trends will likely be a tailwind for PRIM's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

Dr. Tommy Leonard, Sh., M.Kn15.2 years
Ir. Mok Siu Pen
Director
NamePositionShares%
Dr. I Nyoman Ehrich ListerCommissioner2,190,480,00064.55
Mok Siu PenDirector427,8000.02
Expressed in millions IDR, unless otherwise stated

Ownership

PRIM Ownership

NameNumber of SharesOwnership (%)Value
Dr. I Nyoman Ehrich Lister2,190,480,00064.55118.29B
Public (Scripless)1,185,812,40534.9464.03B
Treasury Stock15,114,7000.450.82B
Public (Scrip)1,600,0000.040.09B
Mok Siu Pen427,8000.020.02B
No data is available for PRIM at the moment.

    Sectors, Indonesia's Financial Data Layer

    We hate spam as much as you do. We do not resell your data.

    Email us at sectors@supertype.ai for enquiries on using Sectors for your business or organization.

    © 2024 Supertype Pte. Ltd.
    (and subsidiary PT. Supertype Teknologi Nusantara)